Medication interactions: insulin or sulfonylureas may change hypoglycemia risk
GLP-1s delay the signal from your stomach to your brain about fullness
In controlled experimental environments, Retatrutide acts as a multi-receptor agonist, engaging the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors
How preventive care can impact weight management While GLP-1s may be growing in popularity, theyre not the only option to help employees with weight loss
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial